Eurofins reinforces its market leadership in pharmaceutical products testing with the acquisition of Sinensis Life Sciences B...
13 January 2016 - 6:15PM
Business Wire
Regulatory News:
Eurofins Scientific (Paris:ERF):
Eurofins Scientific (EUFI.PA), the world leader in
pharmaceutical products testing, announces the acquisition of
Sinensis Life Sciences B.V. (“Sinensis”), the leading provider of
pharmaceutical product testing and cGMP Quality Control (QC)
services in the Netherlands.
Sinensis is the reference laboratory for both microbiology and
chemistry testing for biopharmaceutical products in the domestic
market, and has a presence in Europe, Asia and the US. The company
employs about 150 staff, serving the pharmaceutical and
biotechnology industries throughout the Netherlands. Since
inception, Sinensis has consistently grown well above Eurofins’
annual organic growth objective, and expects to generate revenues
in excess of EUR 13.5m for 2015, the majority of which from
biopharmaceutical products testing. The company is also active in
biosafety testing and biological R&D, chemical R&D, and in
cGMP manufacturing.
Sinensis’ competencies are consistent with Eurofins’
market-leading biopharmaceutical testing capabilities, and
specifically with the competencies of Eurofins Lancaster, the
global reference in biopharmaceutical testing. Therefore, the
acquisition strengthens the Group’s geographical footprint and its
position as the market leader in this stable and consistently
growing pharmaceutical services segment. Furthermore, this
acquisition reinforces the Group’s platform to further accelerate
the deployment of the most advanced testing methodologies to
support the pharmaceutical and biotechnology industries across the
entire drug development cycle in Europe.
Sinensis CEO Dr. Ruud Santing ads: “On behalf of all Sinensis
shareholders I’m happy that the strong market position that
Sinensis and its affiliated companies have generated can be further
strengthened within the globally active Eurofins Group.”
Comment from Dr. Gilles Martin, Eurofins CEO: “The acquisition
of Sinensis further strengthens Eurofins’ global leadership in the
rapidly-growing pharmaceutical products testing market. We look
forward to strengthening Sinensis’ testing portfolio and operating
footprint by providing access to the full range of services and
capabilities of the Eurofins Group.”
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific is the world leader in food, environment and
pharmaceutical products testing. It is also one of the global
market leaders in agroscience, genomics, discovery pharmacology and
central laboratory services. In addition, Eurofins is one of the
key emerging players in specialty clinical diagnostic testing in
Europe and the USA.
With over 20,000 staff and 200 laboratories across 39 countries,
Eurofins offers a portfolio of over 130,000 reliable analytical
methods for evaluating the safety, identity, composition,
authenticity, origin and purity of biological substances and
products, as well as for innovative clinical diagnostic. The Group
provides its customers with high-quality services, accurate results
on time and expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities around the
world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgement
of Eurofins Scientific’ management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantee can be made as to their validity.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160112006461/en/
For more information, please visit
www.eurofins.com or contact:Eurofins Investor
Relations+32-2-766 1620ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jul 2023 to Jul 2024